Agentes espasmolíticos: Classificação química

Spasmolytics are drugs that relieve spasticity, a condition characterized by involuntary muscle contractions, muscle stiffness, weakness, and painful muscle spasms. These agents work through different mechanisms: some are centrally acting and affect the spinal cord, while others are direct agents that work on skeletal muscle cells themselves.

Alpha-2 agonists such as tizanidine bind to alpha-2-adrenoceptors and inhibit the release of glutamate, an excitatory neurotransmitter. They also promote glycine release, which causes chloride influx into postsynaptic neurons, reducing their excitability. This dual mechanism provides potent suppression of spasticity through complementary inhibitory pathways.

GABA mimetics such as baclofen activate GABAB receptors, inducing hyperpolarization of neuronal membranes and reducing their excitability. They also inhibit the release of excitatory neurotransmitters and inactivate sensory, motor, and interneurons in the brain and spinal cord, suppressing muscle spasticity.

Benzodiazepines such as diazepam bind to the allosteric site of GABAA receptors, facilitating chloride ion influx into neurons. This hyperpolarizes the neuronal membrane and inhibits neurotransmission, reducing spasticity particularly in the spinal cord. However, sedation can occur at doses required to reduce muscle tone.

Centrally acting spasmolytics fall into three chemical classes: alpha-2 agonists like tizanidine, GABA mimetics like baclofen, and benzodiazepines like diazepam. Each class targets different receptors and neurotransmitter systems in the central nervous system to reduce muscle excitability and spasticity through distinct mechanisms.

Centrally acting spasmolytics affect the spinal cord by modulating neurotransmitter release and neuronal excitability, while directly acting muscle relaxants work on skeletal muscle cells themselves. This distinction in site of action determines their therapeutic profiles and potential side effects in treating muscle spasticity.

Alpha-2 agonists like tizanidine use a dual mechanism to reduce neuronal excitability: they inhibit glutamate release, removing excitatory signaling, while simultaneously promoting glycine release, which enhances inhibitory chloride influx into postsynaptic neurons. This combined action provides potent suppression of spasticity through complementary inhibitory pathways.